emperor-preserved-heart-failure-full-data

Landmark trial demonstrates empagliflozin is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction  In this clinical first for adults with heart failure with preserved ejection fraction, empagliflozin demonstrated an impressive 21  percent relative risk reduction in the composite primary endpoint of cardiovascular death or hospitalization for heart failure1The benefit in the primary endpoint was independent of ejection fraction or diabetes status1Empagliflozin also reduced the relative risk of first and recurrent hospitalizations for heart failure by 27  percent and significantly slowed kidney function decline1Results from the Phase III EMPEROR-Preserved trial were presented today at the European Society of Cardiology Congress 20212  and published in The New England Journal of Medicine1
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news